AXDX - アクセレレ―ト・ダイアグノスティックス (Accelerate Diagnostics Inc.) アクセレレ―ト・ダイアグノスティックス

 AXDXのチャート


 AXDXの企業情報

symbol AXDx
会社名 Accelerate Diagnostics Inc (アクセレレ―ト・ダイアグノスティックス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アクセレレイト・ダイアグノスティクス(Accelerate Diagnostics Inc.)は重大な感染症の診断を通じて患者のアウトカムを開発するソリューションを提供するインビトロ診断会社である。同社のin vitro診断プラットフォームであるAccelerate Phenoシステムは、生細菌または真菌細胞が特定の抗生物質に耐性かまたは感受性かを決定する抗生物質感受性試験(AST)を行うための遺伝子型技術(ID)、感染性病原体および表現型技術を利用する 。同社は単一の患者サンプルから直接病原体を検出・同定し、続いて同定結果に基づいて抗菌剤感受性試験を行う。Accelerate PhenoTest BCキットは、高い罹患率と死亡リスクを伴う生命を脅かす状態である菌血症または真菌血症の疑いのある患者に、IDとASTの結果を提供する。Accelerate Phenoシステムは、ウォークアウェイの自動化を特長とし、固定計測器と一回使用のテストキットで構成される。   アクセレレ―ト・ダイアグノスティックスは米国で医療診断機器を製造、販売。「ID/ASTシステム」の名前で感染性病原体の同定と薬剤感受性試験向け機器、検査キットを提供。敗血症と呼吸器感染などの診断のためにグラム陽性菌とグラム陰性菌の抗生物質への感受性を検査。   Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
本社所在地 3950 South Country Club Road Suite 470 Tucson AZ 85714 USA
代表者氏名 John Patience ジョン・ペイシェンス
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-863-8088
設立年月日 30072
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 239人
url www.acceleratediagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/axdx
adr_tso
EBITDA EBITDA(百万ドル) -72.46400
終値(lastsale) 18.4197
時価総額(marketcap) 997021337.403
時価総額 時価総額(百万ドル) 974.57450
売上高 売上高(百万ドル) 5.44000
企業価値(EV) 企業価値(EV)(百万ドル) 892.66950
当期純利益 当期純利益(百万ドル) -77.40700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Accelerate Diagnostics Inc revenues increased from $1.2M to $2.5M. Net loss increased 44% to $44M. Revenues reflect Domestic(United States) segment increase of 71% to $1.8M Foreign-World ex-United States (Region) segment increase from $167K to $678K. Higher net loss reflects Other Sales general and administrative increase of 48% to $23.2M (expense).

 AXDXのテクニカル分析


 AXDXのニュース

   Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results  2021/02/23 21:15:00 PR Newswire
TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020. "We were pleased with the improvement in our go-live execution over the course of 2020, which drove a…
   Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time  2021/02/01 13:00:00 PR Newswire
TUCSON, Ariz., Feb. 1, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time. A…
   Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results  2021/01/12 11:00:00 PR Newswire
TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below. 2020 Fourth…
   Global Bloodstream Infection Testing Market (2020 to 2024) - Featuring Abbott Laboratories, Accelerate Diagnostics and Becton Among Others - ResearchAndMarkets.com  2020/12/07 11:24:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Bloodstream Infection Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The publisher has been monitoring the bloodstream infection testing market and it is poised to grow by USD 691.32 million during 2020-2024, progressing at a CAGR of 9% during the forecast period. The reports on the bloodstream infection testing market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well
   Accelerate Diagnostics Reports Third Quarter 2020 Financial Results  2020/11/05 21:29:00 PR Newswire
TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid revenue growth in the third quarter, driven by continued steady utilization within our installed…
   Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results  2021/02/23 21:15:00 PR Newswire
TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020. "We were pleased with the improvement in our go-live execution over the course of 2020, which drove a…
   Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time  2021/02/01 13:00:00 PR Newswire
TUCSON, Ariz., Feb. 1, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time. A…
   Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results  2021/01/12 11:00:00 PR Newswire
TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below. 2020 Fourth…
   Global Bloodstream Infection Testing Market (2020 to 2024) - Featuring Abbott Laboratories, Accelerate Diagnostics and Becton Among Others - ResearchAndMarkets.com  2020/12/07 11:24:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Bloodstream Infection Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The publisher has been monitoring the bloodstream infection testing market and it is poised to grow by USD 691.32 million during 2020-2024, progressing at a CAGR of 9% during the forecast period. The reports on the bloodstream infection testing market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well
   Accelerate Diagnostics Reports Third Quarter 2020 Financial Results  2020/11/05 21:29:00 PR Newswire
TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid revenue growth in the third quarter, driven by continued steady utilization within our installed…
   Critical Contrast: DiaSys (OTCMKTS:DYXC) and Accelerate Diagnostics (OTCMKTS:AXDX)  2020/10/22 22:30:56 Daily Political
DiaSys (OTCMKTS:DYXC) and Accelerate Diagnostics (NASDAQ:AXDX) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of current ratings for DiaSys and Accelerate Diagnostics, as reported by […]
   Brokerages Set Accelerate Diagnostics Inc (NASDAQ:AXDX) Price Target at $19.00  2020/10/20 16:00:41 The Olympia Report
Accelerate Diagnostics Inc (NASDAQ:AXDX) has been given an average recommendation of “Hold” by the six analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have assigned a buy recommendation to the company. The average 1 […]
   Accelerate Diagnostics Announces Virtual Product Demo Day and Schedules Call to Review Third Quarter 2020 Results  2020/10/12 13:05:00 PR Newswire
TUCSON, Ariz., Oct. 12, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it will host a virtual Investor Product Demo Day for investors and analysts on Tuesday, October 20, 2020 at 11:00 a.m. Eastern Time. The event will include an inside look at the Company's…
   Antimicrobial Susceptibility Testing Market 2020 Analysis : bioMérieux SA, Danaher, BD, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Liofilchem S.r.l., Accelerate Diagnostics, Inc  2020/09/28 18:31:43 OpenPR
Global Antimicrobial Susceptibility Testing Market, By Product (Automated Laboratory Instruments, Susceptibility Testing Disks), Methods (Dilution, Disk Diffusion, E-test & Others), Type (Antibacterial Testing, Antifungal Testing), Application (Clinical Diagnostics, Epidemiology), End User (Diagnostic Centers and Hospitals, Pharmaceutical and Biotechnology Companies, Contract
   Accelerate Diagnostics Announces New FDA Clearance for Accelerate PhenoTest® Improvements  2020/09/16 13:00:00 PR Newswire
TUCSON, Ariz., Sept. 16, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that the Company has received U.S. Food and Drug Administration (FDA) clearance for a new suite of product enhancements to the Accelerate Pheno® system, which improve performance and…

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アクセレレ―ト・ダイアグノスティックス AXDX Accelerate Diagnostics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)